[go: up one dir, main page]

MA38399A1 - Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique - Google Patents

Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique

Info

Publication number
MA38399A1
MA38399A1 MA38399A MA38399A MA38399A1 MA 38399 A1 MA38399 A1 MA 38399A1 MA 38399 A MA38399 A MA 38399A MA 38399 A MA38399 A MA 38399A MA 38399 A1 MA38399 A1 MA 38399A1
Authority
MA
Morocco
Prior art keywords
heart failure
formulation
useful
tablet form
treating acute
Prior art date
Application number
MA38399A
Other languages
English (en)
Other versions
MA38399B2 (fr
Inventor
Mingda Bi
Robert Kuehl
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38399(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Publication of MA38399A1 publication Critical patent/MA38399A1/fr
Publication of MA38399B2 publication Critical patent/MA38399B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne certaines formulations pharmaceutiques d'omécamtiv mécarbil et leurs procédés de préparation et d'utilisation.
MA38399A 2013-03-14 2014-03-14 Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique MA38399B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785763P 2013-03-14 2013-03-14
PCT/US2014/027104 WO2014152236A1 (fr) 2013-03-14 2014-03-14 Composés hétérocycliques et leurs utilisations

Publications (2)

Publication Number Publication Date
MA38399A1 true MA38399A1 (fr) 2017-01-31
MA38399B2 MA38399B2 (fr) 2020-12-31

Family

ID=50549466

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44637A MA44637B1 (fr) 2013-03-14 2014-03-14 Composes hétérocycliques et leurs utilisations
MA38399A MA38399B2 (fr) 2013-03-14 2014-03-14 Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA44637A MA44637B1 (fr) 2013-03-14 2014-03-14 Composes hétérocycliques et leurs utilisations

Country Status (42)

Country Link
US (16) US9988354B2 (fr)
EP (3) EP2968173B1 (fr)
JP (5) JP6498658B2 (fr)
KR (2) KR102474467B1 (fr)
CN (3) CN105120844A (fr)
AP (1) AP2015008789A0 (fr)
AR (2) AR095542A1 (fr)
AU (2) AU2014240049C1 (fr)
BR (2) BR112015023417B1 (fr)
CA (2) CA2902646C (fr)
CL (1) CL2015002708A1 (fr)
CR (1) CR20150549A (fr)
CY (2) CY1122695T1 (fr)
DK (2) DK2970123T3 (fr)
EA (1) EA031185B1 (fr)
ES (2) ES2750676T3 (fr)
HK (1) HK1218080A1 (fr)
HR (2) HRP20201967T1 (fr)
HU (2) HUE052355T2 (fr)
IL (2) IL240788B (fr)
JO (1) JOP20140114B1 (fr)
LT (2) LT2970123T (fr)
MA (2) MA44637B1 (fr)
ME (1) ME03566B (fr)
MX (3) MX2015012429A (fr)
MY (2) MY204971A (fr)
NZ (1) NZ711225A (fr)
PE (1) PE20151786A1 (fr)
PH (2) PH12019500176B1 (fr)
PL (2) PL2968173T3 (fr)
PT (2) PT2970123T (fr)
RS (2) RS59536B1 (fr)
RU (1) RU2663663C2 (fr)
SA (1) SA515361088B1 (fr)
SG (2) SG11201507258PA (fr)
SI (2) SI2968173T1 (fr)
SM (2) SMT201900563T1 (fr)
TN (1) TN2015000380A1 (fr)
TW (1) TWI667026B (fr)
UA (1) UA117011C2 (fr)
UY (1) UY35449A (fr)
WO (2) WO2014152270A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552404A (en) 2004-06-17 2010-04-30 Cytokinetics Inc Compounds, compositions and methods
EP2968173B1 (fr) * 2013-03-14 2020-10-14 Amgen Inc. Composés hétérocycliques et leurs utilisations
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物
WO2016210240A1 (fr) 2015-06-26 2016-12-29 Amgen Inc. Traitement combiné comprenant un activateur de la myosine cardiaque et un inhibiteur des canaux if du nœud sinusal
AU2018290983B2 (en) 2017-06-30 2023-11-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
EP4265597A3 (fr) * 2017-06-30 2023-11-22 Amgen Inc. Synthèse d'omecamtiv mecarbil
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
EP3594199B1 (fr) 2018-07-09 2020-07-01 F.I.S.- Fabbrica Italiana Sintetici S.p.A. 2-fluoro-3-nitrotoluène cristallin et son procédé de préparation
WO2020014406A1 (fr) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Formes à l'état solide d'omecamtiv mecarbil et d'omecamtiv mecarbil dihcl
WO2020037164A1 (fr) * 2018-08-17 2020-02-20 Amgen Inc. Sel et formes cristallines d'omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
PH12021552190A1 (en) 2019-03-12 2022-08-22 Amgen Inc Polymorphs and cocrystals of a cardiac troponin activator
US20220185791A1 (en) * 2019-03-12 2022-06-16 Amgen Inc. Polymorphs of a cardiac troponin activator
WO2021053175A1 (fr) 2019-09-19 2021-03-25 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041198A4 (fr) * 2019-10-09 2023-08-16 Dr. Reddy's Laboratories Limited Formes solides de dichlorhydrate d'omecamtiv mecarbil et procédés associés
AU2021221106A1 (en) 2020-02-10 2022-09-22 Amgen Inc. Omecamtiv mecarbil tablet
JP2022039996A (ja) * 2020-08-26 2022-03-10 アムジエン・インコーポレーテツド Ｍｃｌ－１阻害剤処方物
MX2023005455A (es) 2020-11-12 2023-07-27 Amgen Inc Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
WO2022177927A1 (fr) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil
US11702380B2 (en) 2021-03-10 2023-07-18 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2024081611A1 (fr) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Méthodes de traitement de l'insuffisance cardiaque par administration d'activateurs de sarcomère cardiaque
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788775B1 (fr) 1999-01-22 2001-04-13 Pf Medicament Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique
GEP20043334B (en) 1999-12-23 2004-03-10 Pfizer Prod Inc Hydrogel-Driven Drug Dosage Form
GB0124455D0 (en) 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
EP1438043A2 (fr) 2001-10-17 2004-07-21 Aventis Pharma Deutschland GmbH Methode de reduction du diabete type 2 chez des patients a risque eleve
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
NZ552404A (en) * 2004-06-17 2010-04-30 Cytokinetics Inc Compounds, compositions and methods
WO2007054975A1 (fr) 2005-11-08 2007-05-18 Panacea Biotec Ltd Compositions pharmaceutiques destinees au traitement de troubles cardiovasculaires et d'autres troubles associes
PE20100743A1 (es) 2005-11-15 2010-11-25 Glaxo Group Ltd Nuevos procedimientos y formulaciones
WO2007070683A2 (fr) 2005-12-15 2007-06-21 Cytokinetics, Inc. Entites chimiques, compositions et procedes
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
WO2007078839A2 (fr) * 2005-12-19 2007-07-12 Cytokinetics, Inc. Composes, compositions et methodes
US7639112B2 (en) 2007-04-25 2009-12-29 Sony Corporation Fuse device with integrated switch
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
US9492468B2 (en) 2008-10-03 2016-11-15 Pericor Therapeutics, Inc. Methods and compositions for treatment of acute heart failure
US9253433B2 (en) 2012-11-27 2016-02-02 International Business Machines Corporation Method and apparatus for tagging media with identity of creator or scene
EP2968173B1 (fr) 2013-03-14 2020-10-14 Amgen Inc. Composés hétérocycliques et leurs utilisations
MX2015012416A (es) * 2013-03-14 2016-04-07 Amgen Inc Compuestos heterociclicos y sus usos.
WO2016123291A1 (fr) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues de 2-(tert-butylamino)-4-((1r,3r,4r) -3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide
WO2016210240A1 (fr) 2015-06-26 2016-12-29 Amgen Inc. Traitement combiné comprenant un activateur de la myosine cardiaque et un inhibiteur des canaux if du nœud sinusal
EP4265597A3 (fr) 2017-06-30 2023-11-22 Amgen Inc. Synthèse d'omecamtiv mecarbil
AU2018290983B2 (en) 2017-06-30 2023-11-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
EP3594199B1 (fr) 2018-07-09 2020-07-01 F.I.S.- Fabbrica Italiana Sintetici S.p.A. 2-fluoro-3-nitrotoluène cristallin et son procédé de préparation
WO2020014406A1 (fr) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Formes à l'état solide d'omecamtiv mecarbil et d'omecamtiv mecarbil dihcl
WO2020037164A1 (fr) 2018-08-17 2020-02-20 Amgen Inc. Sel et formes cristallines d'omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053175A1 (fr) 2019-09-19 2021-03-25 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
EP4041198A4 (fr) 2019-10-09 2023-08-16 Dr. Reddy's Laboratories Limited Formes solides de dichlorhydrate d'omecamtiv mecarbil et procédés associés
WO2021136477A1 (fr) 2020-01-03 2021-07-08 苏州科睿思制药有限公司 Co-cristal de dichlorhydrate du composé i et son procédé de préparation et son utilisation
AU2021221106A1 (en) 2020-02-10 2022-09-22 Amgen Inc. Omecamtiv mecarbil tablet
MX2023005455A (es) 2020-11-12 2023-07-27 Amgen Inc Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
WO2022177927A1 (fr) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil
US11702380B2 (en) 2021-03-10 2023-07-18 Amgen Inc. Synthesis of omecamtiv mecarbil
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
ES2750676T3 (es) 2020-03-26
KR102474467B1 (ko) 2022-12-05
JP2016513683A (ja) 2016-05-16
US20220153700A1 (en) 2022-05-19
US20180312469A1 (en) 2018-11-01
US20240217933A1 (en) 2024-07-04
IL241089B (en) 2019-10-31
CA2902646C (fr) 2022-08-16
US20160016906A1 (en) 2016-01-21
ES2837038T3 (es) 2021-06-29
JP7174132B2 (ja) 2022-11-17
HK1218544A1 (en) 2017-02-24
CY1123633T1 (el) 2022-03-24
MA44637B1 (fr) 2021-04-30
MX363347B (es) 2019-03-20
CN108785265B (zh) 2024-10-08
NZ711225A (en) 2020-06-26
UA117011C2 (uk) 2018-06-11
US20200399221A1 (en) 2020-12-24
JP2022023891A (ja) 2022-02-08
PE20151786A1 (es) 2015-12-11
US20250243163A1 (en) 2025-07-31
US10421726B2 (en) 2019-09-24
PT2970123T (pt) 2019-10-28
RS59536B1 (sr) 2019-12-31
JP6966590B2 (ja) 2021-11-17
PL2970123T3 (pl) 2020-03-31
IL240788A0 (en) 2015-10-29
MY204971A (en) 2024-09-25
WO2014152236A1 (fr) 2014-09-25
EA201591728A1 (ru) 2016-01-29
TN2015000380A1 (en) 2017-01-03
CA2902646A1 (fr) 2014-09-25
CA2902436A1 (fr) 2014-09-25
JP2019059746A (ja) 2019-04-18
SA515361088B1 (ar) 2018-07-22
US11472773B2 (en) 2022-10-18
SG11201507258PA (en) 2015-10-29
BR112015022857B1 (pt) 2022-10-25
AR095542A1 (es) 2015-10-21
MX2015012414A (es) 2016-04-25
CA3147180A1 (fr) 2014-09-25
PH12019500176B1 (en) 2023-08-11
HK1218512A1 (zh) 2017-02-24
RU2663663C2 (ru) 2018-08-08
MX2015012429A (es) 2016-04-07
CN105209437A (zh) 2015-12-30
PL2968173T3 (pl) 2021-03-08
ME03566B (fr) 2020-07-20
UY35449A (es) 2014-09-30
CY1122695T1 (el) 2021-03-12
EA031185B1 (ru) 2018-11-30
SMT201900563T1 (it) 2019-11-13
US20140309235A1 (en) 2014-10-16
AU2014239995B2 (en) 2018-07-26
US20240101517A1 (en) 2024-03-28
SG10201706656RA (en) 2017-09-28
LT2968173T (lt) 2021-03-25
US12221417B2 (en) 2025-02-11
AR129504A2 (es) 2024-09-04
MX2021001231A (es) 2021-04-12
US20220298114A1 (en) 2022-09-22
EP2968173B1 (fr) 2020-10-14
CA3147180C (fr) 2024-04-23
US20200331859A1 (en) 2020-10-22
RS61215B1 (sr) 2021-01-29
US11884630B2 (en) 2024-01-30
DK2970123T3 (da) 2019-10-21
JP6689942B2 (ja) 2020-04-28
PH12019500176A1 (en) 2020-11-04
EP2970123A1 (fr) 2016-01-20
HUE046285T2 (hu) 2020-02-28
IL240788B (en) 2020-09-30
AU2014240049C1 (en) 2019-03-07
JP6783138B2 (ja) 2020-11-11
US11958809B2 (en) 2024-04-16
US9951015B2 (en) 2018-04-24
PT2968173T (pt) 2020-12-18
CN105209437B (zh) 2018-09-18
AU2014240049A1 (en) 2015-09-10
MA44637A1 (fr) 2019-08-30
CL2015002708A1 (es) 2016-03-11
BR112015022857A2 (pt) 2017-07-18
EP2968173A1 (fr) 2016-01-20
US20200277261A1 (en) 2020-09-03
TW201524507A (zh) 2015-07-01
IL241089A0 (en) 2015-11-30
US12275704B2 (en) 2025-04-15
KR20220045014A (ko) 2022-04-12
HRP20201967T1 (hr) 2021-03-05
US20240317687A1 (en) 2024-09-26
KR102374159B1 (ko) 2022-03-15
AP2015008789A0 (en) 2015-10-31
NZ750950A (en) 2020-09-25
US9988354B2 (en) 2018-06-05
EP3821882A1 (fr) 2021-05-19
US20230044617A1 (en) 2023-02-09
HK1218080A1 (zh) 2017-02-03
PH12015501998A1 (en) 2016-01-11
KR20150136063A (ko) 2015-12-04
LT2970123T (lt) 2019-11-11
AU2014240049B2 (en) 2018-07-19
CN105120844A (zh) 2015-12-02
BR112015023417A2 (pt) 2017-07-18
CR20150549A (es) 2016-01-04
BR112015023417B1 (pt) 2023-10-17
JP2020125307A (ja) 2020-08-20
CN108785265A (zh) 2018-11-13
EP2970123B1 (fr) 2019-08-14
HRP20191728T1 (hr) 2019-12-13
AU2014239995A1 (en) 2015-09-10
SI2970123T1 (sl) 2019-12-31
RU2015143643A (ru) 2017-04-18
US20250376444A1 (en) 2025-12-11
HUE052355T2 (hu) 2021-04-28
SI2968173T1 (sl) 2021-04-30
US20200079736A1 (en) 2020-03-12
HK1219484A1 (zh) 2017-04-07
PH12015501998B1 (en) 2016-01-11
DK2968173T3 (da) 2020-12-21
JP6498658B2 (ja) 2019-04-10
SMT202000685T1 (it) 2021-01-05
US20180273479A1 (en) 2018-09-27
TWI667026B (zh) 2019-08-01
JOP20140114B1 (ar) 2021-08-17
US11384053B2 (en) 2022-07-12
MA38399B2 (fr) 2020-12-31
MY186048A (en) 2021-06-17
JP2016519071A (ja) 2016-06-30
WO2014152270A1 (fr) 2014-09-25
EP2970123B2 (fr) 2025-12-10

Similar Documents

Publication Publication Date Title
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
CA2956871C (fr) Composes actifs envers des bromodomaines
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX340985B (es) Compuestos de n-heteroarilo.
PH12014501991B1 (en) Phenicol antibacterials
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
MX375222B (es) Compuestos y su uso para reducir los niveles de ácido úrico
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
WO2016030899A8 (fr) Méthodes de traitement de la sclérose latérale amyotrophique
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12018502139A1 (en) Phosphaplatin liquid formulations
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
MX2018001528A (es) Composicion farmaceutica que comprende sumatriptan para tratamiento de migraña.
EA033077B1 (ru) Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение
MA38426B1 (fr) Compositions antibiotiques de ceftolozane
UA88138U (ru) Лекарственное средство в форме перорального раствора для лечения и профилактики ишемии тканей организма